Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation

Abstract

Objective To validate the robust predictive values of tumor vascularity and reactive cutaneous capillary endothelial proliferation (RCCEP) in combination treatment of transarterial chemoembolization (TACE) and camrelizumab for patients with advanced hepatocellular carcinoma (HCC) and then select the potential candidates who would survive best from such treatment. Methods The clinical data of 113 patients with advanced HCC treated with TACE and camrelizumab from January 2019 to December 2021 were analyzed retrospectively. Mann Whitney U -test was used to evaluate the correlation between vascular distribution and RCCEP and tumor response; Kaplan Meier technique was used to evaluate time to progress (TTP) and overall survival (OS), and log rank test was used for comparison; multivariate Cox regression analysis was used to evaluate the related influencing factors. Results The TTP and OS of TACE combined with carrelizumab in patients with advanced HCC were 7.1 and 14.3 months. Hypervascularity and development of RCCEP were good predictors of TTP (HR 2.561, P < 0.001; HR 1.486, P = 0.032) and OS (HR 2.854, P < 0.001; HR 1.634, P = 0.011). The median TTP and OS of patients with hypervascularity and RCCEP were 10.6 and 19.3 months, which were better than those with only hypervascularity (6.8 months, P = 0.016; 11.6 months, P = 0.003) and only RCCEP (6.2 months, P = 0.039; 13.5 months, P = 0.042), as well as those with neither (3.8 months, P < 0.001; 7.4 months, P < 0.001). Conclusion Tumor hypervascularity and development of RCCEP were favorable predictive factors for the combination treatment of TACE and carrelizumab, with both of which the patients survived longest and might be the potential candidates.

A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative

“…It was important to pay attention to the unique adverse reactions associated with specific medications. For example, Camrelizumab has been associated with a unique adverse reaction known as Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) 13,28 . The incidence of RCCEP with Camrelizumab is approximately 77.4%, but most cases were grade 1–2 adverse reactions.…”

“…For example, Camrelizumab has been associated with a unique adverse reaction known as Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP). 13 , 28 The incidence of RCCEP with Camrelizumab is approximately 77.4%, but most cases were grade 1–2 adverse reactions. Grade 3 or higher RCCEP occurs in only 1.1% of cases, and there have been no reports of grade 4 adverse events or deaths related to RCCEP.…”